The Manufacturers Life Insurance Company Increases Stock Position in Option Care Health, Inc. $OPCH

Key Points

• The Manufacturers Life Insurance Company increased its stake in Option Care Health by 8.8%, owning 1,651,489 shares worth approximately $57.7 million.
• Insider buying activity included Director Harry M. Jansen Kraemer, Jr. purchasing 36,000 shares while Director Timothy P. Sullivan bought 20,000 shares in recent transactions.
• Option Care Health reported a net margin of 3.93% and revenue of $1.42 billion for the previous quarter, surpassing analysts' expectations.

The Manufacturers Life Insurance Company boosted its holdings in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 8.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,651,489 shares of the company's stock after purchasing an additional 133,497 shares during the quarter. The Manufacturers Life Insurance Company owned 1.01% of Option Care Health worth $57,720,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in OPCH. Northwestern Mutual Wealth Management Co. boosted its stake in Option Care Health by 1,492.9% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock worth $31,000 after acquiring an additional 836 shares in the last quarter. Brooklyn Investment Group increased its stake in shares of Option Care Health by 186.6% in the first quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock worth $42,000 after buying an additional 780 shares during the period. Public Employees Retirement System of Ohio increased its position in Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after purchasing an additional 332 shares during the period. Bessemer Group Inc. boosted its holdings in shares of Option Care Health by 62.3% during the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after buying an additional 599 shares in the last quarter. Finally, Wealthquest Corp bought a new position in Option Care Health in the 1st quarter worth about $66,000. 98.05% of the stock is currently owned by institutional investors and hedge funds.

Option Care Health Stock Up 1.7%

NASDAQ:OPCH traded up $0.49 during trading hours on Wednesday, hitting $28.93. 1,900,211 shares of the company's stock traded hands, compared to its average volume of 1,861,633. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.00 and a current ratio of 1.52. Option Care Health, Inc. has a twelve month low of $21.39 and a twelve month high of $35.53. The stock's fifty day moving average price is $29.47 and its two-hundred day moving average price is $31.61. The firm has a market cap of $4.70 billion, a P/E ratio of 23.14, a P/E/G ratio of 1.75 and a beta of 0.82.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.01. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The firm had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same quarter last year, the firm posted $0.30 EPS. The company's revenue was up 15.4% on a year-over-year basis. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, research analysts expect that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Insider Activity at Option Care Health

In related news, Director Timothy P. Sullivan bought 20,000 shares of the business's stock in a transaction on Thursday, August 21st. The shares were purchased at an average cost of $27.51 per share, with a total value of $550,200.00. Following the acquisition, the director owned 49,229 shares of the company's stock, valued at $1,354,289.79. This represents a 68.43% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of the firm's stock in a transaction on Wednesday, August 20th. The shares were bought at an average cost of $27.15 per share, with a total value of $977,400.00. Following the completion of the acquisition, the director directly owned 375,390 shares in the company, valued at approximately $10,191,838.50. This represents a 10.61% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.64% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on OPCH shares. Citigroup reiterated an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. JMP Securities upped their target price on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a report on Thursday, July 31st. Finally, Barrington Research reissued an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a research report on Thursday, July 10th. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.75.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.